In contrast, there was no correlation of NT50 or RBD IgGs with the levels of COVID-19 signature chemokine antibodies (against CCL19, CCL22 and CXCL17), or with the sum of all chemokine IgG reactivities (Extended Data Fig. 3d). This evidence concerns the gene CCL22 and COVID-19.